Thank you, Johnson.
new met improvement primary over metastatic We a of Paclitaxel cancer. important a are breast pivotal in of the an This excited X Oral IV oral significant class study Phase that today very anti-cancer to announce drugs. and endpoint paclitaxel showing Encequidar milestone development represents in the in
first ahead Johnson now Orascovery As platform. towards our from our submission mentioned, we are NDA moving
overall A in population. to-treat metastatic typical treatment cancer efficacy radiologists at XXX two Patient of criteria. using algorithm and to The by balanced responses. was consecutive an in demographics enrolled breast response the were the two infant patients response tumor with independent ratio were X:X X.X two the were groups. a RECIST total IV assessments made in timepoints Blinded independent computer primary tumor rate confirmed of of endpoint the Oral Paclitaxel adjudicator of paclitaxel use and assign
intensive report to of study response to XX% that significant analysis. its primary rate showing efficacy an a the We XX% to compared met are overall pleased paclitaxel, compared with improvement statistically standpoint, our IV treatment in
improvement P paclitaxel higher on which to based on response equal analysis IV were populations than or also in statistically all greater excluding non-evaluable significant compared and other responses was X.XX patients in less control. values rates to improvements versus There would give analysis.
strong progression at X.XXX Paclitaxel Importantly, favored free overall in survival in values IV were and of over Oral both X.XX a there and survival paclitaxel cutoff XXXX, trends July of respectively. XX, date that P with
terms those paclitaxel. this was duration Paclitaxel had many of benefit twice There to in process responses duration as that confirmed days than response. patients compared confirmed on of serve XXX More with IV of other responses on Oral
follow-up. PFS and improve are to still upon expect OS trend we continuing we continue may patients, As that monitor to
a side dose patients only X% and limiting paclitaxel in potential Encequidar the neuropathy previous only significant studies, a observed result on by important XX% with the break-free Oral lower paclitaxel and a Paclitaxel incidence oral of Furthermore tolerated IV IV major our in XX% well severity confer is marketplace. Paclitaxel had and in Oral to of is of line Oral for This Mitigating patients. patients. with paclitaxel. products versus paclitaxel. versus neuropathy Paclitaxel effect Finally, neuropathy, as X% our IV was neuropathy very will advantage a patients dosing in was of Compared
to As treatment improve patients it and outcomes. longer stay will potentially allow some on
the Oral results The safety a in were neutropenia and Overall the Paclitaxel similar showed Oral more the arthralgia, effects myalgia, alopecia, incidence neutropenia group. and groups pleased for incidence safety was rate X also gastrointestinal of in are Paclitaxel both were very with there lower higher of There slightly Paclitaxel a group. more the Paclitaxel. The Oral profile also we grade and group. side slightly in Oral in infection
PK Phase oral monotherapy anti-cancer and we preliminary of following X the sarcoma study, Oral Based class other have in these the angiosarcoma on results Paclitaxel of X drugs study, profile generated the Phase the the new results project of and studies a and X, to as Encequidar characteristics.
improve weeks follow-up. First, may of breast one OS cancer, metastatic IV Early over better efficacy trends profile over paclitaxel long responders breast to observed angiosarcoma, significant duration which metastatic within improvement in in as in continue statistically in in PFS and of cancer confirmed cancer. monotherapy two activity longer breast to in metastatic as response strong onset
myalgia. alopecia, a is currently lower Second, profile, IV improved neuropathy, and of to which lower and paclitaxel incidence much of incidence reason safety major arthralgia,
convenience. hospital visits, use Paclitaxel can IV pre-medications, infusion, of and steroids not antihistamines does at it Oral be home. Third taken require the or intravenous
we for submit As at the publication the reserving we for scientific of also major results discussed, presentation in the clinical will a have studies and future. full meeting we are upcoming
to complete We submission, NDA so currently as we file may our soon possible. are working diligently that as
Athenex previously reminder, if feedback for primary provide we license pivotal the this of U.S. year, would to accept a announced application January met. positive the endpoint that As one results in last a the the FDA in trial it is
is clinical characterized evidence growing supporting trial high by response results a pivotal safety rate this which Oral body Paclitaxel strong positive Importantly, profile. a Encequidar adds and and of to
in In further announced novel cancer, cancers angiosarcoma in we and the with metastatic seen these treated. have these which way serve validate unresectable are transform gastric today potential the study to also addition we successful for to to cancer products our the results regimen breast in cutaneous promising
example working exploring with to therapies. potential are additional for receptor anti-PD-X, combinations and develop anti-MCF Paclitaxel biologics, Oral indications for We
Our combination with is well. study enrolling in Pembrolizumab of Paclitaxel Oral
we provide our continue define further will strategy. details We pipeline as to expansion
assets, our We firmly will to upon paradigm are in studies for studies chemotherapy. establish oral Orascovery oral Orascovery we Phase will Orascovery forward and leader and Irinotecan drugs. pipeline for anti-cancer a Athenex launching establish Paclitaxel, docetaxel. X additional new including looking Oral oral broaden as These oral believe our platform Building a
FDA this the for known investigation that of IND treatment for advanced allow also malignancies. clinical We the application Pegtomarginase quarter patients of also PTXX as the announced with
a approach As treatment deprivation. of to to metabolic biologic product provide is PTXX through cancer designed a novel reminder, candidate arginine a
step a for we Alpha the oncology We are program and potential in and advance pleased believe therapies to other metabolic forward towards this made combination. clinic
planning clinical to are studies initiate soon. of PTXX We
In ongoing of to certain global CIDAL Europe clinical we in in strategic world, our American Limited, with our acquired major and have Latin Together potential pipeline America. operations step initiatives we we Contract these worldwide, for a and across to based various market the important effectiveness and Latin in the formed development. countries. efficiencies operations, our our second effort UK in and June, research America, a operations Research specifically Finally, an increased Latin assets our in the announced Organization Europe, clinical strengthen with expand healthcare in which is expansion a represent subsidiary. capabilities development global And largest cost
expansion Of integrated strategic of course becoming a fits our global the broader fully company. into pharmaceutical vision
the now CFO, over our I financials. call our turn will to Sze, to Randoll? Randoll discuss
